Bisphosphonates Ban: Keeneland, Fasig-Tipton and Ocala Breeders’ Sales Ban Off-Label Use of Popular Navicular Disease Medication in Young Thoroughbreds

Bisphosphonates are a type of medication used to treat osteoporosis in humans. They have been approved by the US Food and Drug Administration since 2014 for treatment of navicular disease in horses older than four. Research in Europe, conducted by Professor Jean-Marie Denoix and others, has also investigated the possible expanded use of one bisphosphonate, tiludronate (Tildren) for other lameness problems, such as bone spavin and osteoarthritic lesions of the thoracolumbar vertebral column. Professor Denoix also led the initial research on Tildren for navicular disease in older horses.

Navicular Syndrome: Does FDA Approval of Tildren and Osphos Change Anything?

From bone to zone: Focus on navicular-type lameness has evolved from concentrating on identifying bone defects visible in radiography to a more dynamic approach to also detect possible soft tissue injury, deteriorating hoof condition and age- or sport-related stress factors. The navicular bone is circled in this distal limb bone model at the University of Nottingham Vet School.

The landscape of treatment options for equine navicular syndrome is set to change this year, as the U.S. Food and Drug Agency (FDA) recently approved two drugs for use in the treatment of this complex lameness problem in the horse's foot. "Tildren" and "Osphos" are two specific medications that cleared the difficult hurdles of the FDA approval process in May 2014.

Hallmarq Standing MRI Presents: Navicular Disease Diagnosis, Then and Now

We have never really understood navicular disease, but maybe we're getting closer. Two horses would have identical lameness symptoms but the radiographs were clean on one, and clearly showed a bone lesion in the other. Some horses stayed lame for years and were never ridden again. Others took a year or so off and, to everyone’s surprise, returned to training.